Browsing by Author "Asker, S."

Now showing 1 - 6 of 6

Association of Intermittent and Continuous Hypoxaemia With Carotid and Brachial Arterial Intima-Media Thicknesses
(Univ West indies Faculty Medical Sciences, 2022) Asker, S.; Asker, M.; Ozgokce, M.; Ozbay, B.
Objective: To assess the carotid and brachial arteries' intima-media thicknesses (IMTs) in cases with intermittent (obstructive sleep apnoea syndrome (OSAS)) and continuous (chronic obstructive pulmonary disease (COPD)) hypoxaemia together with other confounding demographic and biochemical factors. Methods: The study was prospectively performed on 197 patients allocated in three groups: 80 with severe OSAS, 80 with severe COPD patients and 37 healthy controls. These groups were compared in terms of demographics, biochemical markers and IMTs of the right and left carotid and brachial arteries. Results: Carotid and brachial arterial IMTs were found to be higher in both patient groups than the control group (p < 0.001). Similarly, levels of haemoglobin, haematocrit, cholesterol, triglycerides, low-density lipoproteins (LDL), C-reactive protein and D (domain)-dimer were significantly increased in patient groups. Oxygen saturations (p < 0.001) and ejection fractions (p = 0.001) were found to be worse and D-dimer levels (p = 0.010) were elevated more prominently in COPD patients, whereas, cholesterol (p < 0.001), hemoglobin (p = 0.004) and LDL (p = 0.001) levels were higher in the OSAS group. Except the right carotid IMT, which was increased significantly in OSAS patients, IMT measurements were similar in the OSAS and COPD groups (p < 0.001). Conclusion: We have shown that both intermittent and continuous hypoxia result in remarkable alterations in carotid BIT and brachial IMT. Further prospective trials are warranted to confirm and extend these findings, including the biochemical markers, which may aid in the diagnosis and follow-up of patients suffering from hypoxaemia.
Is İt İn Our Genes That We're Going To Have Pulmonary Embolism
(Yuzuncu Yil Universitesi Tip Fakultesi, 2024) Uney, İ.H.; Arisoy, A.; Sunnetcioglu, A.; Mermit Çilingir, B.; Yıldız, H.; Gunbatar, H.; Asker, S.
Pulmonary thromboembolism is a disease with high mortality and morbidity, which can be recurrent, difficult to diagnose, yet preventable and treatable. In this study, our aim was to evaluate comorbidities, risk factors, laboratory results, and clinical scoring in patients diagnosed with pulmonary embolis m. Our primary goal was to detect genetic mutations in cases of pulmonary embolism with acquired risk factors. Our study is a prospective study that includes clinical information, laboratory tests, Wells scoring, admission, and the prospective history of 60 patients with no previous history of venous thromboembolism (VTE) and no history of anticoagulation use. These patients were admitted to the chest diseases outpatient clinic, emergency department, or hospitalized for another reason and diagnosed with pul monary thromboembolism. The mean age of the patients was 59.9 ± 18.7 years. The most common presenting complaints were shortness of b reath and sharp chest pain. Nearly half of the patients had at least one comorbid disease. There was at least one genetic/congenital risk factor in all cases, and at least two risk factors were present in more than half of the cases. The most common mutati ons were plasminogen activator inhibitor type 1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR) heterozygote mutations. Pulmonary embolism continues to be a more prevalent disease with increasing age and associated risk factors. Since there is at least one acquired risk factor in all of our cases, we believe that almost every patient may have an acquired risk factor if the history is thoroughly investigated. We also believe that genetic or thrombophilic conditions may be detected in almost all cases diagnosed with pulmonary embolism. It has been concluded that immobilization and obesity are the most common preventable risk factors associated with VTE. © 2024, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
An Overlooked Cause of Resistant Hypertension; Upper Airway Resistance Syndrome
(Excerpta Medica inc-elsevier Science inc, 2014) Asker, M.; Asker, S.; Kucuk, U.; Kucuk, H. O.
Pulmonary Langerhans Cell Histiocytosis: Two Cases With Varied Radiologic Findings
(Yuzuncu Yil Universitesi Tip Fakultesi, 2016) Gunbatar, H.; Yavuz, A.; Sertogullarindan, B.; Ekin, S.; Asker, S.; Sayır, F.; Bayram, I.
Pulmonary Langerhans Cell Histiocytosis (PLCH) is an idiopathic interstitial lung disease with Langerhans cell infiltration in the lung. PLCH X has non-spesific symptoms, and most patients have smoking history. A combination of stellate nodules, reticular and nodular opacities, upper zone cysts or honeycombing, preservation of lung volume and costophrenic angle sparing are highly specific for PLCH. To contribute to the literature, two cases are presented. First case is 30 years old man with 10 pack/years smoking history was admitted with cough and persevering interstitial opacities. Second case is 34 years old man with 15 pack/years smoking history was admitted with persistant cough. On thorax CT the first case had reticulonodular opacities at the perifery of the upper and middle zones, second case had multiple parenchymal cystic nodular lesions. Open lung biopsy performed, immunohistochemical examination CD1a, CD68, S100 detecting antigenpositive and histologically and radiologically confirmed diagnosed of PLCH. © 2016, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
Search for a Genetic Factor for Pleuroparenchymal Fibroelastosis (Ppfe)
(Nature Publishing Group, 2019) Bolukbasi, E. Yildiz; Ozkaya, S.; Asker, S.; Tolun, A.
Using Propofol for Flexible Bronchoscopy
(Yuzuncu Yil Universitesi Tip Fakultesi, 2015) Arısoy, A.; Demirkiran, H.; Ekin, S.; Gunbatar, H.; Asker, S.; Sertogullarindan, B.
Propofol is a sedative-hypnotic drug with rapid onset and recovery time. There are limited number of studies in which propofol was used for bronchoscopy. In this current study, we evaluated our patients who received propofol sedation for bronchoscopy in our clinic and investigated the usefulness of the procedure for both patients and physicians We prospectively evaluated patients who had bronchoscopy in our clinic between 2012 January and 2013 January. We recorded demographic features, indications for bronchoscopy, procedures of bronchoscopy, duration of the procedures, minor and major adverse events and hemodynamic parameters of the patients. All patients were monitored until they were discharged from the bronchoscopy unit. In total, 97 patients were included in the study. The mean age of the participants was 65 years, 60 of them were male (61%) and 37 were women (39%). Major indications were lung lesions that were suspected to be central or peripheral lung cancer. Other indications were mediastinal-hilar lymph nodes, hemoptysis, tuberculosis, atelectasis, chronic cough and tracheomalacia. Mean propofol dose was 90 mg in patients who had biopsy and 70 mg for those who did not have biopsy. Mean duration of the procedure was 14 minutes in those who had biopsy and 10 minutes in those who did not have biopsy. One patient had epistaxis after receiving topical lidocaine and two patients had respiratory arrest that required ambulation with a mask. Thirty-five patients (36%) had desaturation, which was reversed by providing adequate oxygenation. Propofol is a useful and applicable sedative-hypnotic for patients and physicians for fiberoptic bronchoscopy. © 2015, Yuzuncu Yil Universitesi Tip Fakultesi, Universitas Indonesia. All rights reserved.